Avalo Therapeutics Shares Rise 35% on Trial

Avalo Therapeutics shares rose 35% after its Phase 2 LOTUS trial met primary HiSCR75 endpoint, showing 42% response versus 25.6% placebo.
The 253‑patient trial showed secondary gains on HiSCR50, IHS4 reduction, and tunnel count, with only headache and nausea reported.
Avalo launched an underwritten offering of common stock and warrants, with Leerink, TD Cowen and BofA as bookrunners, to fund Phase 3 and working capital.
Avalo will present full LOTUS results at an upcoming medical congress, supporting its move to a registrational Phase 3 program.